A high-resolution x-ray reflectometer system that is for characterization of mirrors for use with advanced light sources and includes a table, arc, and sample stage. The table and arc may be made of the same material, in some configurations that material is granite. An x-ray source and detector are mounted on the arc. The arc is movable along the surface of the table in a first direction, and the sample stage is moveable on the table surface in a second direction, perpendicular to the first direction. The sample stage can accommodate a sample with a thickness of 5 cm or more. Vertical lifting stages at each end of the sample stage allow for independent height adjustment of the ends, allowing for tiling of the sample. An autocollimator is mounted at the apex of the arc to characterize the tilt of a sample on the sample stage.
G01N 23/20008 - Constructional details of analysers, e.g. characterised by X-ray source, detector or optical systemAccessories thereforPreparing specimens therefor
2.
SYSTEMS AND METHODS FOR CONCURRENT REACTION-BONDED JOINING AND DENSIFICATION
A method can include providing two or more parts. The two or more parts can include a first part and a second part. The method can include disposing a source material between the first part and the second part. The method can include joining and densifying the first part and the second part by reacting a liquid with the source material.
Embodiments of the disclosure may comprise a photo-dependent proximity labeling system comprising an activatable probe and a retrievable substrate. The activatable probe may be, for example, an integrin binding peptide operatively coupled to a lumichrome molecule, and the retrievable substrate may be, for example, a biotin phenol. In some aspects, the activatable probe is activatable by light, thereby inducing labeling of adjacent molecules with a retrievable substrate. Also disclosed are methods for labeling proteins, identifying protein interactions or binding partners, and methods for identifying a therapeutic target in an individual using a composition of the disclosure.
A method for coating a coolant metal on a ceramic substrate comprises modification of the substrate surface to provide an oxide free surface upon which the coolant metal is deposited.
A method for modifying argyrodite-type material. The argyrodite-type material is exposed to a fluorine precursor. The argyrodite-type material may have a carbonate coating that has formed, such as due to exposure to air, with such carbonate coating at least partially removed by exposure to the fluorine precursor. The argyrodite-type material may further be doped by fluorine after exposure to the precursor. Further, the argyrodite-type material may have a capping layer formed thereon.
C23C 16/44 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
Employing undulator devices as x-ray radiation sources requires high magnetic field strength and precision for generating high intensity, high coherence radiation. A magnetic field tunable undulator device is described. The undulator device includes a first magnet array disposed along a central axis of the undulator device, and a second magnet array disposed along the central axis, opposite the first magnetic array, across a gap distance. First and second structural keepers are respectively coupled to the first and second magnetic arrays to support positions of the first and second magnet arrays. A plurality of tuning elements are (i) disposed along the central axis, (ii) physically coupled to at least one of the first magnet array or the second magnet array, and (iii) configured to tune the magnetic field profile along the central axis between the first magnet array and the second magnet array.
Typical chemical vapor deposition (CVD) systems are unable to analyze a sample during CVD fabrication. A system and method for performing material deposition and in-situ analysis of a sample during CVD synthesis is described. The system includes a deposition chamber having an outer chamber wall surrounding a chamber volume and an inner sleeve disposed inside of the chamber volume with a buffer region between the outer chamber wall and the inner sleeve. A sample mount is disposed in the deposition volume to support a position and orientation of a sample in the deposition volume during CVD. Gas inlets and gas outlets are in fluid communication with the deposition chamber to respectively allow fluid to flow into, and out of, the deposition chamber. A thermal radiation source provides thermal radiation along a deposition axis to the sample disposed in the deposition volume.
C23C 16/48 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating by irradiation, e.g. photolysis, radiolysis, particle radiation
C23C 16/54 - Apparatus specially adapted for continuous coating
G01N 23/20008 - Constructional details of analysers, e.g. characterised by X-ray source, detector or optical systemAccessories thereforPreparing specimens therefor
8.
PREDICTING PROPERTIES OF BIOLOGICAL ENTITIES USING EVOLUTIONARY TREES
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for predicting a property of an input biological entity. The system generates an evolutionary feature representation of the input biological entity based at least in part on an evolutionary tree, and processes a model input that comprises the evolutionary feature representation sing a machine learning model to generate the prediction for the property of the input biological entity.
Systems and methods are provided herein for training a customized model. A method of constructing a customized generative model, comprising reading a plurality of synthetic images and associated latent representations; presenting each of the plurality of synthetic images to one or more users via a client computing platform; reading a plurality of inputs characterizing a plurality of values for a plurality of associated attributes of each of the plurality of synthetic images; based on the values of the associated attributes and the latent representations, training a regression model to predict the values of the attributes from the latent representations.
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/766 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using regression, e.g. by projecting features on hyperplanes
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
10.
SELECTIVE AND LONG-LIVED SINGLE COMPONENT HETEROGENEOUS ETHYLENE TRIMERIZATION CATALYSTS ENABLED BY SURFACE LITHIATION
A catalyst for selective hexane and/or butene formation from ethylene. The catalyst is formed by grafting Cr or Mn to an inorganic support. The grafted metal site is reduced, forming a catalyst that is selective for selective trimerization of ethylene to hexene and/or butene.
Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs. In aspects, the present disclosure provides a method of preparing MSCs, exosomes, and secretome. In aspects, the present disclosure provides a method of preventing chemotherapy-induced damage in a male mammal.
Provided herein are methods for extracting and separating metals from a mixture of metal oxides comprising: disposing a cathode comprising the mixture of metal oxides, a reducing electrode, and an anode in a solvent comprising a mixture of molten metal hydroxide salts; applying an electrical potential to a cathode, thereby reducing the mixture of metal oxides and forming a mixture of metals; selectively dissolving one or more metal ion species from the mixture of metals into the dried solvent; and applying a potential to the reducing electrode present in the dried solvent to reduce the dissolved metal ion species from the dried solvent to a respective pure metal or mixed metal.
A shredder for minimizing aggregation of whole batteries can include a shaft defining a longitudinal axis and a latitudinal axis. The shredder can include a plurality of teeth disposed on knives which fit on said shaft at an angle to the latitudinal axis selected from 0 degrees and 45 degrees. The teeth can have a first proximal end integrally molded to the shaft and a second free distal end.
H01M 10/54 - Reclaiming serviceable parts of waste accumulators
B02C 18/08 - Disintegrating by knives or other cutting or tearing members which chop material into fragmentsMincing machines or similar apparatus using worms or the like with rotating knives within vertical containers
B02C 18/14 - Disintegrating by knives or other cutting or tearing members which chop material into fragmentsMincing machines or similar apparatus using worms or the like with rotating knives within horizontal containers
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF CHICAGO (USA)
Inventor
Simon, Jonathan
Schuster, David I.
Taneja, Lavanya
Abstract
An optical resonator includes a plurality of mirrors positioned to reflect light along a closed path, thereby defining an optical axis. The optical resonator also includes one or more intracavity lenses positioned along the optical axis to establish a resonator mode whose waist that is located along the optical axis. The optical resonator also includes an intracavity nonlinear optical element that implements a nonlinear frequency-mixing process within the optical resonator. When input light is coupled into the optical resonator to excite the resonator mode, the intracavity nonlinear optical element nonlinearly converts at least some of the input light into nonlinearly generated light. This nonlinearly generated light may then be coupled out of the optical resonator, such as via transmission through one of the mirrors. In some embodiments, the waist is five microns or less. In some embodiments, the finesse of the optical resonator is 100 or less.
A non-aqueous electrolyte comprising a salt, a non-aqueous solvent, and a compound of Formula (I) or Formula (II) or Formula (III) or Formula (IV) or Formula (V):
A non-aqueous electrolyte comprising a salt, a non-aqueous solvent, and a compound of Formula (I) or Formula (II) or Formula (III) or Formula (IV) or Formula (V):
An electrochemical cell includes an anode comprising silicon and an electrolyte comprising a linear carbonate and vinylene carbonate in a concentration of about 11 wt. % to about 80 wt. % based on the weight of the electrolyte. The electrolyte is free of saturated cyclic carbonates conventionally used in lithium-ion batteries.
Employing undulator devices as x-ray radiation sources requires expensive and bulky support systems for operation, which are not robust and lead to limited ranges of generated radiation energies. A force-compensated undulator device is described. The device includes an undulator having first and second magnet arrays disposed along a central axis. The first magnet array is translatable along the central axis. The device further includes a compensator unit disposed adjacent to the first magnet array with the compensator unit having a first row of magnets disposed along a compensator axis with the compensator axis being parallel to the central axis, and a second row of magnets disposed along the compensator axis. The first row of magnets is translatable along the compensator axis. The compensator provides magnetic forces that neutralize the system dynamic magnetic forces generated by the undulator.
Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.
A polymer comprising a plurality of repeat units of formula (I)
A polymer comprising a plurality of repeat units of formula (I)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
wherein each Ar1 and Ar4 is a unit comprising two or more aromatic groups; Ar1 comprises at least one cross-linkable group; Ar4 comprises a substituent selected from —SO3H, —CO2H, —PO3H2, and salts thereof; R1 and R2, and R7 and R8, are independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, aryl, and heteroaryl, each optionally substituted, or R1 and R2, or R7 and R8, together with the carbon atom to which they are attached, form a carbocycle or heterocycle, provided that at least one of R7 and R8 contains an amide group or at least one geminal pair of R7 and R8, together with the carbon atom to which they are attached, forms a carbocycle or heterocycle that contains an amide group; and membranes and membrane electrode assemblies including same.
C08G 10/00 - Condensation polymers of aldehydes or ketones with aromatic hydrocarbons or halogenated aromatic hydrocarbons only
B01J 39/05 - Processes using organic exchangers in the strongly acidic form
B01J 39/19 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
B01J 41/05 - Processes using organic exchangers in the strongly basic form
B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
H01M 8/1027 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having carbon, oxygen and other atoms, e.g. sulfonated polyethersulfones [S-PES]
H01M 8/103 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having nitrogen, e.g. sulfonated polybenzimidazoles [S-PBI], polybenzimidazoles with phosphoric acid, sulfonated polyamides [S-PA] or sulfonated polyphosphazenes [S-PPh]
22.
COMPOSITION AND METHODS FOR TUMOR IMAGING AND TREATMENT
Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.
C07C 271/48 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
23.
ESTROGEN RECEPTOR ALPHA ANTAGONISTS AND USES THEREOF
The disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein n, X1, and R'-R3 are defined herein: Also provided are pharmaceutical compositions comprising a compound disclosed herein, methods of inhibiting estrogen receptor alpha (ERa), methods of treating an estrogen- mediated disease in a subject requiring inhibition of estrogen receptor (ER) alpha (ERa), methods of treating one or more symptoms of menopause in a subject in need thereof, and methods of treating one or more side effects of hormone replacement therapy.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
To address the need in the art, the inventors have comprehensively characterized Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and/or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.
Provided herein are depolymerizable thermally activated delayed fluorescence polymers with exceptional light-emitting properties and programmable depolymerization under specific stressors.
Lithium-ion cells including fluoroether electrolytes and configured to promote lithium intercalation and (de)intercalation within graphite without fluoroether co-intercalation are provided. Processes for preparing the lithium-ion cells are further provided.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 10/0568 - Liquid materials characterised by the solutes
H01M 10/0569 - Liquid materials characterised by the solvents
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Lymphatic, nervous, and tumoral tissues, among others, exhibit physiology that emerges from three-dimensional interactions between genetically unique cells. A technology capable of volumetrically imaging genotypes and morphologies in a single de novo measurement would therefore provide a critical view into the biological complexity of living systems. The present disclosure achieves this by extending DNA microscopy, an imaging modality that encodes a spatio-genetic map of a specimen via a massive distributed network of DNA molecules inside it, to three dimensions and multiple length scales in developing zebrafish embryos.
The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The invention provides a method for fabricating x-ray focusing optics, the method comprising supplying a first cathode forming a first channel, inserting a substrate within the channel; and charging the first cathode to sputter first cathode material to a surface defining the substrate, thereby forming a first zone film onto the surface. Also provided is a monolithic X-ray diffraction lens having sub 10 nanometer resolutions, the lens comprising a substrate overlaid with discrete regions of metal, the regions integrally molded with the substrate.
G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators
C23C 14/04 - Coating on selected surface areas, e.g. using masks
31.
CONCENTRATED SOLAR POWER ELECTRIC POWER PLANT HEAT EXCHANGE MODULE
An additively manufactured heat exchanger adapted for use in extreme environments, such as a concentrated solar power (CSP) electric power plant. The heat exchanger receives a liquid heat transfer fluid at a high temperature and high pressure. The heat exchanger efficiently exchanges heat with a working fluid flowing in a cross-flow or a counter-flow configuration. A first set of channels of the heat exchanger receives liquid heat transfer fluid, such as corrosive molten salt, and a second set of channels receives working fluid, such as super critical carbon dioxide. The heat exchanger transfers heat from the liquid heat transfer fluid to the working fluid.
B22F 1/10 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material
B33Y 80/00 - Products made by additive manufacturing
F28F 1/10 - Tubular elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with projections, with recesses
F28F 21/04 - Constructions of heat-exchange apparatus characterised by the selection of particular materials of ceramicConstructions of heat-exchange apparatus characterised by the selection of particular materials of concreteConstructions of heat-exchange apparatus characterised by the selection of particular materials of natural stone
F28F 21/08 - Constructions of heat-exchange apparatus characterised by the selection of particular materials of metal
Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
33.
POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally. RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A lithium-sulfur battery providing stable, high energy density includes a cathode including sulfur, an anode including lithium metal, and an electrolyte including non-aqueous solvent and an additive including a fluorinated borate or a fluorinated borane; and lithium bis(nonafluorobutanesulfonyl)imide (LiNFBSI).
Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.
A process for charging a discharged electrochemical cell includes applying a voltage bias to the discharged electrochemical cell; and illuminating the cathode, the anode, or both the cathode and the anode with light having a narrow band of wavelengths corresponding to the respective band gaps of the electrode active materials.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
Systems and methods are disclosed for electronic monitoring. A method of electronic monitoring comprises receiving a location of a participant, receiving data associated with the participant, and determining an alert level for the participant based on the data and the location of the participant.
The present disclosure relates to semiconductor heterojunctions incorporating porous semiconductor materials. In one aspect, the present disclosure provides a device comprising a p-type semiconductor material comprising a nanoporous semiconductor layer and a nonporous semiconductor layer that form a heterojunction; and a flexible substrate comprising one or more of polymers on which the p-type semiconductor material is distributed such that the flexible substrate is in contact with the nonporous semiconductor layer.
Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.
The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids. Also provided are detectable antibodies specific for the bridging antigens, kits comprising the reagent compounds and antibody and oligonucleotide reagents, methods of signal amplification using the compounds and reagents of the disclosure, methods of preparation of the compounds and reagents, and compositions comprising the compounds and reagents.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITE DE MONTPELLIER (France)
INSTITUT REGIONAL DU CANCER DE MONTPELLIER (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventor
Pan, Tao
Zhang, Wen
Abstract
In general, the current disclosure relates to pre-queuosine1 (preQ1) affecting mammalian cellular function, including affecting proliferation of the mammalian cell. Aspects herein further show that preQ1 can affect tRNA abundance.
Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB,LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
43.
THIN SULFIDE-BASED SOLID-STATE ELECTROLYTES VIA SPRAY DEPOSITION
A solid electrolyte for solid-state batteries includes a lithium argyrodite film of formula of LinPxSyXz, where X is F, Cl, Br, I, or a mixture of two or more thereof, and where n is 1 to 10, x is 1 to 3, y is 3 to 8, and z is 1 to 3. The lithium argyrodite exhibits a polyamorphous microstructure and may have a thickness of about 1 μm to about 50 μm. The solid electrolyte is formed using spray decomposition deposition.
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
44.
NANOSCALE METAL-ORGANIC FRAMEWORKS WITH X-RAY TRIGGERABLE PRODRUGS FOR COMBINATION RADIOTHERAPY, CHEMOTHERAPY, AND IMMUNOTHERAPY
A metal-organic framework (nMOF) including an X-ray sensitive prodrug is described. For instance, the MOF can include metal-containing secondary building units (SBU) that are linked together via organic bridging ligands where the SBU includes a metal cation that can absorb X-rays and where at least one organic bridging ligand is substituted by a monovalent moiety derived from a therapeutic agent, such as a chemotherapy and/or immunotherapy agent, via a group that includes a bond capable of radical-promoted bond cleavage. Methods of using the MOF to treat diseases, such as cancer, are also described. The methods can include the combination of radiotherapy or radiotherapy-radiodynamic therapy with chemotherapy or immunotherapy.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
This disclosure relates to methods for determining sodium concentration in biological samples. More particularly, this disclosure relates to methods capable of determining Na+ concentration using nucleic acid complexes.
Provided herein are antibodies that bind α-Butyrophilin2A1 (BTN2A1), and diagnostic, therapeutic and research methods of use thereof. In particular, BTN2A1 antibodies are provided with substantially no cross-reactivity with α-Butyrophilin3A1 (BTN3A1), and in certain embodiments exhibiting BTN2A1 antagonism and/or inhibition of Vγ9Vδ2 T-cell activation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The United States of America, as Represented by the Secretary, Department of Health and Human (USA)
President and Fellows of Harvard College (USA)
IIT Research Institute (USA)
Beth Israel Deaconess Medical Center, Inc. (USA)
Inventor
Solway, Julian
Dulin, Nickolai
Rosner, Marsha
Mutlu, Gokhan
Luci, Diane
Maloney, David
Park, Chan Young
Fredberg, Jeffrey
Mccormick, David
Krishnan, Ramaswamy
Abstract
Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
A61P 35/04 - Antineoplastic agents specific for metastasis
C07C 311/16 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 277/52 - Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
C07D 279/12 - 1,4-ThiazinesHydrogenated 1,4-thiazines not condensed with other rings
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method for treating cancer in a subject comprising administering to the subject an immunotherapy after a biological sample from the subject has been analyzed for membrane-localized antigens (mAg).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
Methods of generating light are provided comprising applying an electrical bias to an active region of a quantum dot cascade light emitting device comprising: the active region comprising a film of close-packed, doped, colloidal quantum dots, the quantum dots comprising a core semiconductor characterized by an energy band having quantum states defining an intraband transition between a high energy quantum state and a low energy quantum state, and a pair of electrodes configured to apply the electrical bias, wherein the active region emits light under the electrical bias as carriers undergo the intraband transitions in the core semiconductor of quantum dots in the film, tunnel to other quantum dots in the film, and undergo additional intraband transitions in the core semiconductor of the other quantum dots in the film. The quantum dot cascade light emitting devices are also provided.
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H10K 50/115 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising active inorganic nanostructures, e.g. luminescent quantum dots
inter aliainter alia, concern the ability of certain bacterial consortia to reconstitute a microbiome and re-introduce beneficial metabolites into the microbiome. Certain aspects relate to compositions comprising bacteria capable of the same.
52.
METHODS AND COMPOSITIONS COMPRISING ENGINEERED IL-7 AND IL-12 POLYPEPTIDES FOR TREATING CANCER
The dual therapy involving tumor stroma-binding IL-7 and IL-12 variants led to synergistic antitumor efficacy through suppression of immune exhaustion and promotion of immune memory without compromised tolerability. The disclosure describes a polypeptide comprising an IL-7 polypeptide, or a functional fragment thereof, linked to a extracellular matrix (ECM)-affinity domain. Also described is a nucleic acid encoding a polypeptide of the disclosure and cells comprising the polypeptide(s) or nucleic acid(s) of the disclosure.
53.
METHODS AND COMPOSITIONS FOR REGULATING GENE EXPRESSION
Aspects of the present disclosure are directed to at least methods and compositions for site-specific targeting or RNA and/or pseudouridine installation in RNA, such as mRNA. Provided targeting and/or pseudouridine installation can increase stability of RNA, increase mRNA translation, and/or fine-tune protein expression. Also disclosed herein are compositions, methods, and kits suitable for therapeutic application of site-specific targeting of RNA and/or pseudouridine installation in RNA.
54.
SPATIOTEMPORALLY PATTERNED MULTI-CHANNEL MICROSTIMULATION OF SOMATOSENSORY CORTEX FOR IMPROVED RESOLUTION FORCE FEEDBACK AND PERCEPTION OF TACTILE MOTION AND EDGE ORIENTATION
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (USA)
Inventor
Bensmaia, Sliman J.
Grenspon, Charles M.
Valle, Giacomo
Gaunt, Rob
Hobbs, Taylor
Verbaarschot, Cecile
Lienkamper, Robin
Abstract
Embodiments are provided for stimulation of somatosensory cortex such that (i) the perceptions of force induced thereby exhibit increased levels of discrimination, allowed for finer-resolution perceptions to be achieved, (ii) perceptions of edges or other geometric aspects of objects can be delivered, and (iii) perceptions of motion of objects can be delivered. These embodiments include providing such stimulation to multiple electrodes or other stimulation sites synchronously, with the multiple stimulation sites evoking perceptions whose locations on the hand at least partially overlap. Perception of edges can be evoked by synchronously stimulating multiple stimulation sites somatotopically oriented along the orientation of the edge. Perception of motion can be evoked by providing sequential stimulus from one stimulation site to another, with the interval between sequential stimuli non-overlapping enough to induce perception of motion while close enough in time to evoke a single percept rather than a sequence of discrete percepts.
Products and methods for redirecting the pathological biochemical process of accumulation of reduced pyridine nucleotides under deleterious hypoxia conditions toward the reduction of the precursor salt and the biosynthesis of biologically compatible, antioxidant noble metal nanoparticles and the simultaneous restoring of the tissue redox state are provided. The products and methods have application in the treatment of hypoxia and hypoxia-related diseases and disorders. Such products and methods are also useful in organ transplantation and recovery, in screening of anti-hypoxia agents, and in detecting elevated levels of the reducing equivalents of the redox state, for example, NADH, NADPH, GSH, and TrxSH2, in cells, tissues, or organs.
Aspects herein relate to methods and systems for identifying drug candidates. Also disclosed are candidate molecules identified using the methods and systems disclosed herein.
Aspects of the present disclosure are directed to INCENP-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such INCENP-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using INCENP-targeting polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
58.
METHODS AND COMPOSITIONS COMPRISING ACTIN BINDING PROTEINS
The current disclosure describes light switchable actin binding protein (ABP) built from a photosensitive protein and an ABP. This is accomplished by creating an ABP that is caged and has a weak affinity to actin in the dark and uncaged with a strong affinity for actin in the light. These light-switchable polypeptides can recruit other actin binding proteins of interest to actin filaments spatiotemporally and reversibly. Aspects of the disclosure relate to polypeptides that are useful for labeling actin fibers. Accordingly, the disclosure relates to a polypeptide comprising the amino acid sequence: AXXIXXXA(M)nGVADLIKKFE(X′)n′ (SEQ ID NO:1) or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:1, wherein X is any amino acid, n and n′ are each independently selected from 0 and 1, and X′ is equal to SISKEE.
A non-transitory storage medium stores instructions readable and executable by at least one electronic processor to perform an imaging method). The method includes: obtaining multi-parametric magnetic resonance (MR) imaging data parameterized by a diffusion weighting or perfusion weighting parameter and a magnetization relaxation parameter for a region of interest (ROI) of a patient; determining volume fraction maps of the ROI for each of a plurality of tissue types from the multi-parametric MR imaging data; and controlling a display device to display a tissue composition map comprising or generated from the determined volume fraction maps.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/50 - NMR imaging systems based on the determination of relaxation times
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
60.
QUANTUM COHERENT DEVICES USING A THIN FILM ON SI/SOI PLATFORM
The disclosure is directed to devices, systems, and methods for fabricating doped thin-film structures for quantum communication. The device includes an insulator substrate; a thin-film structure disposed on the insulator substrate, the thin-film structure comprising: a device layer disposed on the insulator substrate, and a doped oxide layer disposed on the device layer; and the thin-film structure comprising a photonic crystal section.
INSTITUTE FOR CANCER RESEARCH d.b.a. THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (USA)
THE UNIVERSITY OF CHICAGO (USA)
Inventor
Wang, Y., Lynn
Lu, Pin
Franzen, Carrie
Abstract
Compositions and methods for the treatment of cancers through the inhibition of Cell-in-Cell Phenomenon are provided herein. Also provided are compositions and methods for modulating the CIC internalization process and identification of agents which modulate the same.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
62.
MICROCHANNEL PLATES WITH STRUCTURED CHANNELS CONSTRUCTED FROM PATTERNED LAMINAE
Planar and non-planar microchannel plates (MCPs) made from patterned, channel-forming laminae are provided. Also provided are methods of fabricating the MCPs by assembling patterned, dielectric laminae into slabs and methods of using the MCPs to detect photons, including gamma rays, neutrons, charged particles, such as electrons and ions, alpha particles, tritons, and fission products. In the methods of fabricating the MCPs, a slab is assembled via the side-by-side stacking of laminae into a slab. Prior to being incorporated into the slab, the surfaces of the laminae are patterned such that they define structured channels for electron multiplication extending through the thickness of the slab. The channels can run parallel or non-parallel, can have uniform or non-uniform shapes and dimensions, and can have interior surfaces with uniform or non-uniform chemical compositions or surface textures.
Methods and systems for state decoding from a signal are provided, including decoding signals using parametrization of dynamical systems. Certain embodiments enable reading a collection of neural signals over a period of time from a brain-machine interface.
G06F 3/00 - Input arrangements for transferring data to be processed into a form capable of being handled by the computerOutput arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
64.
PARTICLE DETECTORS BASED ON DIRECT CONVERSION AT THE SURFACE OF A DENSE MEDIUM
Particle detectors, including gamma ray detectors and neutron detectors, are provided. Also provided are methods of using the detectors to detect particle radiation. The particle detectors use a layer of a particle conversion material to convert incident particles directly into primary electrons or other non-photon particles, such as alpha particles, protons, tritons, gamma rays, or fission products, without the use of a scintillator. The primary electrons and other non-photon particles generate secondary electrons in a secondary electron emission material, and these secondary electrons undergo amplification to generate a secondary electron shower that can be converted into an electronic signal by one or more anodes.
G06T 3/16 - Spatio-temporal transformations, e.g. video cubism
G01N 23/046 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material using tomography, e.g. computed tomography [CT]
A method for determining an optimal sensor set includes identifying a set of possible faults of a thermal hydraulic system and a set of diagnostic objectives. The method also includes obtaining descriptions of sensor sets, which includes: receiving a first description of a first sensor set, and generating, based on the first description, a second description of a second sensor set. The method further includes, for each sensor set: determining a diagnostic capability of the sensor set, and calculating a score of the particular sensor set based on the particular description and the diagnostic capability, wherein a score of a sensor set is increased by a monetary cost of the sensor set and decreased by the sensor set meeting a diagnostic objective. The method also includes identifying the optimal sensor set that has a lowest score of the sensor sets, and displaying an indication of the optimal sensor set.
The disclosure is directed to universal hairpin primer (UHP) nucleic acid molecules for quantifying RNA, including mature microRNA (miRNA), messenger RNA (mRNA), and long noncoding RNA (lncRNA), as well as systems and methods for using same. The UHP nucleic acid molecules comprise a stem-loop structure and a degenerate nucleic acid sequence of 2-10 (e.g., 2-6) nucleotides at the 3′ end, wherein the degenerate nucleic acid sequence hybridizes to the 3′-end of an RNA molecule. The RNA quantification analysis can be carried out by using either the conventional SYBR Green system or the cost-effective universal TaqMan probe-based RT-qPCR system.
Described herein are borate salts useful as additives, binders, and electrolyte salts for solid state lithium ion batteries. In particular, the borate salts of Formula (I), Formula (II) and Formula (III) as described herein:
Described herein are borate salts useful as additives, binders, and electrolyte salts for solid state lithium ion batteries. In particular, the borate salts of Formula (I), Formula (II) and Formula (III) as described herein:
Described herein are borate salts useful as additives, binders, and electrolyte salts for solid state lithium ion batteries. In particular, the borate salts of Formula (I), Formula (II) and Formula (III) as described herein:
can be bound to an existing polymer to provide polymeric binders for ceramic solid state electrolytes that are themselves capable of ion transport independent of the ceramic.
C08L 85/04 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbonCompositions of derivatives of such polymers containing boron
C08G 79/08 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon a linkage containing boron
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventor
King, Sarah B.
Kasthuri, Narayanan
Littlewood, Peter B.
Boergens, Kevin Michael
Li, Ruiyu
Wildenberg, Gregg Anthony
Abstract
An imaging system comprising a light source configured to radiate a biological sample, wherein the light source is optimized for rapid imaging of the biological sample using a photoelectric effect. The system also includes a sample holder configured to secure the biological sample during imaging. The system also includes a stage assembly to which the sample holder is mounted, where stage assembly moves the biological sample during imaging. The system further includes a detector configured to receive electrons emitted from the biological sample in response to radiation from the light source.
Aspects herein relate, in part, to genetically modified bacteria capable of secreting protein of interest using signal peptides. Aspects herein also relate, in part, to presenting proteins of interest on a bacterial cell using truncated cell surface proteins.
The present disclosure provides methods and compositions for inducing trained immunity, preventing infections, improving immune responses, modulating the activity of at least one protein in the BCL family of proteins, increasing the efficacy of a vaccine, and reducing the risk of a secondary tumor in a subject diagnosed with a primary cancer.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Optofluidic devices configured confine liquid crystals within a fluidic channel under the application of acoustic waves and pressure-driven flow and related methods of use are described.
G02F 1/11 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on acousto-optical elements, e.g. using variable diffraction by sound or like mechanical waves
G02F 1/1337 - Surface-induced orientation of the liquid crystal molecules, e.g. by alignment layers
H04R 23/00 - Transducers other than those covered by groups
72.
VIBRATIONAL MICROCAVITY MODIFIED CHEMICAL REACTIONS
Provided herein are devices for utilizing vibrational strong coupling (VSC) in a chemical reaction comprising a reaction chamber defined in a housing, at least one inlet for introducing one or more reactants into the reaction chamber, at least one outlet for removing one or more reactants and/or one or more reaction products form the reaction chamber, and a window defined on opposed first and second sides of the housing and comprising a material which does not strongly absorb infrared radiation and arranged such that infrared radiation directed from a source outside of the housing can enter into the reaction chamber. Also provided are methods of modifying chemical reactions as well as catalyzing chemical reactions.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
73.
BIOADHESIVE POLYMER SEMICONDUCTOR FILMS AND TRANSISTORS FOR INTIMATE BIOINTERFACES
Bioadhesive polymer semiconductor ("BASC") films, including a bioadhesive polymer and a semiconducting polymer, that is a double-network film, are provided herein. Methods of making the film, including in situ preparation of the bioadhesive polymer, are further provided. Organic electrochemical transistors including the film are further provided.
Methods for selectively extracting lithium ions from samples containing lithium ions and sodium ions are provided. The methods take advantage of the phase separation of lithium-containing phases and sodium-containing phases in inorganic intercalation compounds having one-dimensional (1D) olivine crystal structures, which are also referred to herein as hosts. Benefitting from this phase separation, the methods described herein improve the intercalation of lithium ions in the hosts, relative to the intercalation of sodium ions, by pre-seeding the intercalation compounds with lithium to form high-lithium content solid state phases that favor lithium intercalation over sodium intercalation.
An electrochemical cell includes a cathode comprising a cathode active material, an anode comprising an anode active material, and an electrolyte comprising a sulfonyl solvent, a terminally fluorinated glycol ether, and a salt. Other electrochemical cells include a cathode, an anode, a separator, and an electrolyte comprising: a lithium salt; a cathode stabilizing additive selected from the group consisting of vinylene carbonate, vinyl ethylene carbonate, LiBF2(C2O4), LiB(C2O4)2, LiPF2(C2O4)2, LiPF4(C2O4), LiPF6, LiAsF6, CsF, CsPF6, Li2(B12X12-iHi), Li2(B10X10-i′Hi′), or a mixture of any two or more thereof, wherein the cathode stabilizing additive is not the same as the lithium salt, wherein each X is independently at each occurrence a halogen, i is an integer from 0 to 12 and i′ is an integer from 0 to 10; and a fluorinated organosulfate compound.
A system for generating a multi-element atom array includes a first spatial light modulator that transforms a first input laser beam into a first modulated laser beam and a second spatial light modulator that transforms a second input laser beam into a second modulated laser beam. The first input laser beam has a first wavelength while the second input laser beam has a second wavelength different from the first wavelength. The system includes a beam combiner that combines the first and second modulated laser beams into a combined laser beam. The system includes a lens that focuses the combined laser beam. The first spatial-light modulator is controlled to generate a first array of optical tweezers at the first wavelength for trapping a first atomic element. The second spatial-light modulator is controlled to generate a second array of optical tweezers at the second wavelength for trapping a second atomic element.
A compact two-dimensional (2D) scanning magnet for scanning ion beams is provided. The compact 2D scanning magnet may include a vertical field trapezoidal coil and a horizontal field trapezoidal coil that is disposed proximate to the vertical field trapezoidal coil and is rotated about an axis relative to the vertical field trapezoidal coil. The vertical field trapezoidal coil may include a top coil that is configured to receive a first input electrical current flowing in a first direction, and a bottom coil that is configured to receive a second input electrical current flowing in the first direction. The horizontal field trapezoidal coil may include a left coil that is configured to receive a third input electrical current flowing in a second direction, and a right coil that is configured to receive a fourth input electrical current flowing in the second direction.
Aspects of the present disclosure are directed to nanoparticle compositions comprising synthetic DNA binding peptides, as well as methods of generating such peptides and methods for use of such peptides in, for example, DNA binding, modifying gene expression, and treatment of various conditions such as cancer, fibrosis, and diabetes. Certain aspects provide synthetic DNA binding dimers comprising two modified bZIP peptides, each comprising a modified basic domain and a modified leucine zipper domain and linked via an interpeptide linker (e.g., a side-by-side interpeptide linker). Also disclosed are universal methods for generating high affinity synthetic DNA binding dimers from any bZIP protein.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A method of improving Faradaic efficiency in an electrochemical device includes providing a catalyst at an electrode of the electrochemical device. The catalyst includes a nanoparticle comprising a metal or metal alloy. The nanoparticle is selected to improve catalytic performance in the electrochemical device. The catalyst further includes an electron-conductive nano-zeolitic framework encasing the nanoparticle. The nano-zeolitic framework includes a hollow three-dimensional framework defining a catalyst surface, an internal cavity in which the nanoparticle is disposed, and a plurality of pores extending through the nano-zeolitic framework. The plurality of pores have a size and shape selected to block molecules corresponding to undesired reactions in the electrochemical device. The method further includes selectively promoting a desired reaction at the catalyst surface and selectively blocking the undesired reactions at the catalyst surface.
C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
Compositions and methods for simultaneous determination of pH and potassium (K+) concentration in biological samples are provided. The methods employ labeled nucleic acid complexes formed by the hybridization of four single stranded nucleic acid molecules.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
81.
METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR TREATING CANCER
The current disclosure provides for techniques and approaches for the generation of autologous mutant neoantigen-specific, TCR-engineered T cells used for adoptive transfer in treatment of cancer patients. Also provided are surrogate cancer cells, which is a personalized cell system that can be used for vaccination and TCR discovery in cancer patients.
Electrode active materials with lithiated spinel character are described herein. An electrode active material having the general empirical formula Li2Ni2-x-yMnxM′yO4 (Formula I); wherein M′ comprises ions of one or more metal other than Ni and Mn; 0
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
83.
SLOW-WAVE HYBRID MAGNONICS BASED ON INTERACTING MAGNONS AND SPOOF SURFACE PLASMON POLARITONS
A method for broadband, high-efficiency spin wave transduction adopts a slow-wave structure to enhance the interaction of electromagnetic waves and spin waves.
Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.
A quantum computing system providing quantum processing as a service includes a quantum computing device and a server including at least one classical processor. The server is configured to: create a first job queue that includes a plurality of jobs configured to be executed on the first quantum computing device; receive, from a client device, a request for execution of a quantum program; add a first job entry to the first job queue for the request, the first job entry includes a quantum circuit for a first job; perform an optimization process on the quantum circuit of the first job; transmit the updated quantum circuit to the first quantum computing device for execution by the first quantum computing device using the plurality of qubits; receive, from the quantum computing device, execution results from the execution of the updated quantum circuit; and transmit the execution results to the client device.
A printhead for direct write vapor deposition comprises a nozzle body including a reservoir for holding a material to be printed and a nozzle head protruding from the nozzle body. The nozzle head includes a nozzle opening for ejection of the material as a vapor-phase ink. The nozzle opening is in fluid communication with the reservoir. The nozzle head may protrude from the nozzle body a distance of at least 10 microns. A system for direct write vapor deposition includes the printhead, a heat source positioned to heat the printhead, a substrate in opposition to the nozzle opening for deposition of the vapor-phase ink, and an x-y-z motion stage configured to move the substrate relative to the printhead.
B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
C23C 16/01 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes on temporary substrates, e.g. on substrates subsequently removed by etching
87.
CONTINUOUS MONITORING WITH NANO-DIAMOND HYDROGEL IN MICRONEEDLES
The present disclosure relates to a microneedle having a responsive hydrogel disposed therein. The responsive hydrogel can include optically active particles and capture agents. In particular, such a microneedle can be provided within a device or a monitoring system. Methods of using such microneedles are provided, such as for detection of an analyte.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
A quantum data center includes a quantum computer and a transceiver. The transceiver is in communication with the quantum computer and is operable to communicate with a remote user via a quantum communication network. The quantum computer (i) receives, via the transceiver, a quantum input state from the remote user, (ii) stores, in a quantum random access memory, a plurality of database states in a plurality of database qudits forming a database register, (iii) queries the quantum random access memory with the quantum input state to retrieve, from the database register, a quantum output state that is based on one or more of the plurality of database states, the quantum output state being disentangled from the quantum input state and the plurality of database states, and (iv) transmits, via the transceiver, the quantum output state to the remote user.
The current disclosure relates to new compact Cas12f CRISPR/Cas systems with improved activities, such as improved endonuclease activity. Aspects of the disclosure relate to engineered AsCas12f polypeptides comprising one or more amino acid substitutions relative to SEQ ID NO: 1, engineered CRISPR/Cas system ancillary component oligonucleotides such as sgRNA-v2, and polynucleotides encoding said polypeptides and/or functional RNA species. Also disclosed are vectors, compositions, and methods comprising and/or comprising use of the same.
Aspects of the disclosure relate to methods for treating sepsis in a patient comprising administering a PLA2G5 targeting molecule, fatty acids, LPA inhibitors, and/or other compositions to the patient.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A method of forming MAX phase structures having one or more apertures includes filing a green body having one or more apertures with an insert powder and sintering while applying a load to the insert filled green body to from the MAX phase structure.
B22F 5/10 - Manufacture of workpieces or articles from metallic powder characterised by the special shape of the product of articles with cavities or holes, not otherwise provided for in the preceding subgroups
Aspects of the present disclosure are directed to growth hormone (GH)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such GH-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of acromegaly using GH-targeting polypeptides.
Provided herein are methods and compositions for the inhibition of NSUN1 and/or NSUN2 interactions with certain binding partners, such as bromodomain-containing protein 4 (BRD4) and elongating RNA polymerase II (eRNAPII). Also provided herein are methods and compositions for treatment of drug resistant cancer, particularly venetoclax and/or 5-AZA resistant cancer.
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 231/54 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
Provided are methods of generating strain in membrane layers, including diamond membrane layers, in heterostructures. In embodiments, a method of forming a strained membrane layer comprises heating a heterostructure, the heterostructure comprising a membrane layer, a substrate, and a bonding layer between the membrane layer and the substrate, under conditions to cure the bonding layer and form a bonded heterostructure, wherein the membrane layer and the substrate have a thermal expansion ratio mismatch; and cooling the bonded heterostructure under conditions to convert the membrane layer in the bonded heterostructure to a strained membrane layer characterized by a strain profde comprising anon-zero strain value, wherein the strained membrane layer comprises a suspended region and a supported region and wherein the suspended region exhibits a strain value greater than a strain value exhibited by the supported region. Bonded heterostructures comprising the strained membrane layers are also provided.
B05D 5/12 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain a coating with specific electrical properties
95.
ELECTROLYTES FOR LOW TEMPERATURE LITHIUM BATTERIES
An electrochemical cell configured to operate at low temperatures includes a cathode comprising a cathode active material, an anode comprising an anode active material, a separator disposed between the cathode and the anode, and an electrolyte. The electrolyte includes a fluorinated cyclic carbonate, a solid electrolyte interphase (SEI)-forming additive salt, a metal fluorophosphate salt, and a fluorinated organic compound.
H01M 10/0567 - Liquid materials characterised by the additives
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 10/0568 - Liquid materials characterised by the solutes
H01M 10/0569 - Liquid materials characterised by the solvents
The present disclosure relates to core-shell particles, in which a particle can include a core having one or more color centers and a shell disposed around the core. Also provided herein are methods of preparing such particles, devices including one or more core-shell particles, as well as methods for detecting a target using such devices.
G01N 33/551 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
97.
BIOCOMPATIBLE SURFACE FOR QUANTUM SENSING AND METHODS THEREOF
The present disclosure relates to a device having various layers that are supported on a substrate having one or more color centers. Such layers can include one or more capture agents configured to capture a target. Methods of making and using such devices are also described herein.
Embodiments are directed to kits and methods of treating a breast cancer patient with a glucocorticoid receptor antagonist with or without an anticancer agent or compound after the patient has been determined to be susceptible to treatment with the glucocorticoid receptor antagonist.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
99.
QUANTUM SOURCE CODING WITH A QUANTUM SORTING NETWORK
A quantum source coding method includes: initializing a quantum register having a plurality of nodes: loading a unary-coded message into the quantum register; loading an address state into an address register of each message node of the quantum register; sorting the message nodes based on a data register such that the message nodes form a message-sorted sequence; and applying, for each message node at an end of the message-sorted sequence, a CNOT gate to the address state of each of the register's message nodes and output nodes. The method also includes: unsorting the message nodes; sorting the nodes based on the address register such that the nodes form a fully-sorted sequence; applying, for each pair of adjacent nodes in the fully-sorted sequence having the same address state, a CNOT gate to the data registers of each pair; and unsorting the nodes to return the fully-sorted sequence to the initial sequence.
The inventors have made TadA variants with improved activities, such as improved based editing in certain genomic contexts and altered editing window. Aspects of the disclosure relate to a polypeptide comprising SEQ ID NO: 1, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO: 1, wherein the one or more amino acid substitutions comprise a substitution at amino acid (23, 27, 36, 47, 48, 51, 76, 82, 106, 108, 109,110, 111, 114, 119, 122, 123, 126, 127, 146, 147, 152, 154, 155, 156, 157, 161, 166, 167), and combinations thereof.
